KRYS250117P220000
- 32.39
- 0.000.00%
Krystal Biotech Newsroom
(KRYS) - Analyzing Krystal Biotech's Short Interest
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Krystal Biotech (NASDAQ:KRYS) Shareholders Are Still up 158% Over 5 Years Despite Pulling Back 7.6% in the Past Week
Krystal Biotech: Saxena's Appointment Effective Jan 15
Express News | Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
Press Release: Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $196
Promising Clinical Data and Platform Potential Drive Buy Rating for Krystal Biotech
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Krystal Biotech Is Maintained at Buy by Chardan Capital
Krystal Biotech Early Lung Cancer Data 'Promising,' Says H.C. Wainwright
Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity
Express News | Krystal Biotech Announces Initial Results From Ongoing KYANITE-1 Study Of KB707; Observed 27% Objective Response Rate And 73% Disease Control Rate As Of Data Cut-Off On Dec. 6
Express News | Krystal: Majority of Treatment-Related Adverse Events Been Mild to Moderate in Severity & Transient, With No Grade 4 or 5 Adverse Events Observed
Express News | Krystal Biotech Inc - Reports 27% Orr and 73% Dcr in Nsclc Trial
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.24 Million in Common Stock
Insider Sale: President of $KRYS (KRYS) Sells 911 Shares